← Back
Data updated: Mar 10, 2026
DAIICHI SANKYO
OncologyCardiovascularGastroenterology
DAIICHI SANKYO is a biotechnology company focused on Oncology, Cardiovascular, Gastroenterology. Key products include SAVAYSA.
2015
Since
5
Drugs
-
Trials
10
Approved (2yr)
Key Drugs
Recent Activity
ENHERTU 2025-12-15
Labeling
ENHERTU 2025-12-15
Efficacy
TURALIO 2025-08-27
REMS
DATROWAY 2025-06-23
Type 1 - New Molecular Entity
ENHERTU 2025-01-27
Efficacy
ENHERTU 2025-01-27
Labeling
DATROWAY 2025-01-17
Type 1 - New Molecular Entity
TURALIO 2025-01-03
Labeling
VANFLYTA 2024-06-25
Labeling
ENHERTU 2024-04-05
Efficacy
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 69%
3 drugs Phase 3: 22 Phase 2: 22 Phase 1: 43
Cardiovascular 16%
1 drugs Phase 3: 8 Phase 2: 2 Phase 1: 2
Gastroenterology 7%
0 drugs Phase 3: 2 Phase 2: 3 Phase 1: 6
Respiratory 6%
1 drugs Phase 3: 2 Phase 2: 1 Phase 1: 2
Metabolic 2%
0 drugs Phase 2: 3
Pipeline Strength Pro
Loading...
Competitors Pro
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Cardiovascular
BRACCO specialty
Cardiovascular, Oncology, Metabolic, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Metabolic